Case ReportBevacizumab (Avastin) for Corneal Neovascularization-Corneal Light Shield Soaked ApplicationMackenzie, Sarah E MD; Tucker, William R MBBS; Poole, Tom R G FRCOphthAuthor Information From the Eye Unit, Frimley Park Hospital, Frimley, Camberley, Surrey, UK. Received for publication February 12, 2008; revision received June 16, 2008; accepted July 5, 2008. Reprints: Tom R. G. Poole, the Eye Unit, Frimley Park Hospital, Portsmouth Road, Frimley, Camberley, Surrey GU16 7UJ, UK (e-mail: [email protected]). Cornea: February 2009 - Volume 28 - Issue 2 - p 246-247 doi: 10.1097/ICO.0b013e3181861cc9 Buy Metrics Abstract Purpose: To describe a case where topical bevacizumab (Avastin) was used in an attempt to reduce corneal neovascularization before corneal graft. Methods: Topical bevacizumab was applied through a corneal light shield for 20 minutes once a week for 11 weeks to the cornea. Results: Corneal vascularization was not reduced. Conclusions: Topical bevacizumab was not effective in this case at reducing corneal neovascularization. Copyright © 2009 Wolters Kluwer Health, Inc. All rights reserved.